Haemostatix has developed a new class of active clotting agent, or "haemostat" for the control of bleeding. The company has pioneered a new approach to haemostasis that is based on a peptide that binds to the protein fibrinogen, inducing the rapid and targeted formation of clots. This innovative technology platform is being used to develop a pipeline of topical and systemic products to prevent or control different forms of bleeding.
Haemostatix's lead product is PeproStat™, a topical haemostat that is applied directly to wounds to rapidly control bleeding during surgery or trauma. PeproStat has a novel mode of action that is fast and effective. It is manufactured from blood-free components and will be available in a range of ready-to-use formulations. Current products are typically blood-derived and often require preparation prior to use.
Haemostatix is based at BioCity, Nottingham, United Kingdom.